217 results on '"Long, Meixiao"'
Search Results
2. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy
3. A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
4. SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling
5. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
6. The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets
7. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia
8. A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
9. PI3K p110[delta] inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression
10. IκBβ acts to inhibit and activate gene expression during the inflammatory response
11. Abstract 828: DNA origami nanostructures as a targeted payload delivery system
12. Abstract 2966: Exploring the therapeutic potential of a novel Siglec-6 targeted bispecific antibody to selectively kill leukemia cells
13. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
14. Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment
15. Ibrutinib treatment improves T cell number and function in CLL patients
16. The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)
17. A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
18. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement
19. Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity
20. Systematic illumination of druggable genes in cancer genomes
21. Systematic Pan-Cancer Characterization of Nuclear Receptors Identifies Potential Cancer Biomarkers and Therapeutic Targets
22. Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75
23. Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
24. Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients
25. IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic Leukemia
26. Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
27. T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment
28. Clinical Activity of Axicabtagene Ciloleucel in Adult Patients with Richter Syndrome
29. Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/− rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia
30. Effect of induction intensity on survival in patients with acute myeloid leukemia.
31. Association of post-transplant outcomes with induction intensity in patients with acute myeloid leukemia.
32. Type of prior genotoxic insult determines the genomic characteristics of therapy‐related myeloid neoplasms
33. SUSD2 suppresses CD8+T cell antitumor immunity by targeting IL-2 receptor signaling
34. CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?
35. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment
36. Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
37. Type of prior genotoxic insult determines the genomic characteristics of therapy-related acute myeloid leukemia.
38. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry
39. T Regulatory Cells Maintain Intestinal Homeostasis by Suppressing γδ T Cells
40. Nuclear Factor-κB Modulates Regulatory T Cell Development by Directly Regulating Expression of Foxp3 Transcription Factor
41. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
42. Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
43. Differential Role of the Transcription Factor NF-κB in Selection and Survival of CD4+ and CD8+ Thymocytes
44. Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
45. Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
46. Cytopenias after Chimeric Antigen Receptor T-Cells (CAR-T) Infusion; Patterns and Outcomes
47. Modulation of immune checkpoint molecule expression in mantle cell lymphoma
48. Levofloxacin Prophylaxis for Autologous Stem Cell Transplant: A Second Look
49. CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?
50. Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.